Methodology considerations for 'Safety and effectiveness of cannabinoids to Danish patients with treatment-refractory chronic pain' by Horsted et al
Eur J Pain
.
2023 Jul;27(6):661-663.
doi: 10.1002/ejp.2107.
Epub 2023 Mar 21.
Authors
Lars Arendt-Nielsen
1
2
3
4
,
Kristian Kjaer-Staal Pedersen
1
2
,
Lene Dreyer
5
6
,
Salome Kristensen
5
6
,
Sten Rasmussen
6
,
Bo Biering-Sørensen
7
,
Helge Kasch
8
,
Andrew Rice
9
Affiliations
1
Department of Health Science and Technology, Faculty of Medicine, Center for Neuroplasticity and Pain, Aalborg University, Aalborg, Denmark.
2
Center for Mathematical Modeling of Knee Osteoarthritis (MathKOA), Aalborg University, Aalborg, Denmark.
3
Department of Gastroenterology and Hepatology, Mech-Sense, Aalborg University Hospital, Aalborg, Denmark.
4
Steno Diabetes Center North Denmark, Clinical Institute, Aalborg University Hospital, Aalborg, Denmark.
5
Department of Rheumatology, Aalborg University Hospital, Aalborg, Denmark.
6
Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.
7
Department of Neurology, The Neuroscience Center, The National Hospital, Copenhagen University, Copenhagen, Denmark.
8
Department of Neurology, Aarhus University Hospital, Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
9
Pain Research, Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, London, UK.
PMID:
36897232
DOI:
10.1002/ejp.2107
No abstract available
Publication types
Research Support, Non-U.S. Gov't
MeSH terms
Cannabinoids* / adverse effects
Chronic Pain* / drug therapy
Denmark
Humans
Pain, Intractable*
Substances
Cannabinoids